Macedonian Pharmaceutical Bulletin, 72 (Suppl 1) 351 - 352 (2026)
Online ISSN: 1857-8969
DOI: 10.33320/maced.pharm.bull.2026.72.03.170
Short communication

Artificial Intelligence for Real-Time Pharmaceutical Quality Assurance

Aleksandra Talevska Leshoska*, Slavica Dinusheva, Dajana Apostolova[1], Amdi Alili, Jasminka Utevska

FLOWER POWER LLC, Vevchani, Republic of North Macedonia

Introduction

The pharmaceutical industry is undergoing a rapid digital transformation driven by Industry 4.0 technologies such as Artificial Intelligence (AI), Machine Learning, Internet of Things, Process Analytical Technology and advanced data analytics. These technologies are reshaping traditional quality systems by enabling real-time monitoring, predictive control, and automated decision-making (Marta et al., 2022). In this context, AI has emerged as a key enabler of real-time pharmaceutical Quality Assurance (QA), supporting continuous manufacturing and Quality by Design (QbD) principles (Yang et al., 2020; Fitzgerald et al., 2025).

Traditional quality assurance systems rely on end-product testing and retrospective batch review, which may delay detection of deviations and increase the risk of product variability. In contrast, AI-based systems enable proactive quality assurance by analyzing large volumes of process data in real time, identifying trends, detecting anomalies, and predicting potential quality failures before they occur. This transition marks a shift from reactive to predictive and preventive quality management.

AI-driven quality assurance framework

An AI-enabled pharmaceutical QA system typically consists of three integrated components:

Data acquisition layer. This includes IoT sensors, PAT tools, laboratory systems, and manufacturing execution systems. These devices continuously collect real-time data on Critical Process Parameters, Critical Material Attributes, and environmental conditions (Marta et al., 2022; Fitzgerald et al., 2025).

Artificial intelligence layer. This layer includes machine learning algorithms, deep learning models, multivariate data analysis, and hybrid mechanistic-AI models. AI systems process large datasets to identify correlations between process parameters and product quality attributes (Yang et al., 2020; Li et al., 2025).

Decision and control layer. The output of AI models is used for real-time alerts, process adjustments, automated control strategies, and quality decision support systems. This enables immediate intervention when deviations are detected (Gatkal et al., 2026; Fitzgerald et al., 2025).

Applications in pharmaceutical quality assurance

Real-time process monitoring. AI systems continuously monitor manufacturing processes and detect deviations from predefined normal operating ranges. Advanced anomaly detection algorithms identify subtle variations that may not be visible through traditional statistical methods (Yang et al., 2020; Fitzgerald et al., 2025).

Predictive quality control. Machine learning models can predict final product quality based on in-

*aleksandra.leshoska@flowerpower.mk

process data. This supports early decision-making and reduces reliance on end-product testing (Marta et al., 2022; Gatkal et al., 2026).

Automated deviation detection. AI can classify deviations, determine severity, and suggest corrective and preventive actions (CAPA), improving response time and consistency in QA decision-making (Li et al., 2025; Fitzgerald et al., 2025).

Process optimization. AI-driven analytics optimize process parameters such as temperature, mixing speed, flow rates, and pressure to ensure consistent product quality and improved efficiency (Marta et al., 2022; Gatkal et al., 2026).

Digital batch review. AI enables automated batch record review by analyzing electronic production data, reducing manual workload and improving compliance with GMP requirements (Fitzgerald et al., 2025; FDA, 2024).

Integration with QbD and regulatory frameworks

Artificial Intelligence aligns strongly with QbD principles by supporting design space definition, process understanding, and control strategy development. It also enhances Continued Process Verification (CPV) by enabling continuous data evaluation throughout the product lifecycle (Yang et al., 2020).

Regulatory authorities such as the FDA and EMA increasingly support the use of advanced analytics, process modeling, and digital technologies in pharmaceutical manufacturing. AI-based QA systems are aligned with ICH Q8 (Pharmaceutical Development), ICH Q9 (Quality Risk Management), and ICH Q10 (Pharmaceutical Quality System). However, regulatory challenges remain regarding model validation, transparency, and data integrity in AI-driven systems (FDA, 2024; Fitzgerald et al., 2025).

Benefits and challenges

The implementation of AI in real-time QA offers several advantages, including improved product quality, reduced batch failures, faster release times, enhanced process understanding, and lower operational costs. It also strengthens regulatory compliance through continuous monitoring and documentation. However, challenges include data integration from multiple sources, algorithm validation, cybersecurity risks, limited digital maturity in some facilities, and the need for skilled personnel capable of managing AI systems (Li et al., 2025; Gatkal et al., 2026).

Conclusion

AI is transforming pharmaceutical QA by enabling real-time monitoring, predictive analytics, and automated decision-making. By integrating AI with manufacturing systems and quality frameworks, pharmaceutical companies can transition from traditional reactive quality control to proactive and continuous quality assurance. As the industry advances toward Pharma 4.0, AI-based QA systems are expected to become a central component of modern pharmaceutical manufacturing, improving efficiency, compliance, and patient safety.

References

Fitzgerald, L. et al., 2025. Emerging digital innovations in pharmaceutical manufacturing quality. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s12247-025-10272-5

Gatkal, A. et al., 2026. Digital twins in pharmaceutical manufacturing and quality assurance: A predictive approach for smart manufacturing and risk management systems. International Journal of Advanced Research. https://doi.org/10.22271/27889262.2026.v6.i1a.154

Li, L. et al., 2025. Risk analysis of AI and digital manufacturing systems using improved FMEA methods. Systems, 13(1), 48. https://doi.org/10.3390/systems13010048

Marta, M. et al., 2022. Digital twin and AI-assisted continuous manufacturing optimization. International Journal of Pharmaceutics, 626, 122336. https://doi.org/10.1016/j.ijpharm.2022.122336

U.S. Food and Drug Administration (FDA), 2024. Artificial intelligence in pharmaceutical manufacturing and continuous processing. FDA Science Forum. https://www.fda.gov

Yang, X. et al., 2020. Artificial intelligence and digital twins in pharmaceutical manufacturing: A review. Processes, 8(9), 1088. https://doi.org/10.3390/pr8091088